CD54 is a surrogate marker of antigen presenting cell activation

Cancer Immunology, Immunotherapy

Volumn 57, Issue 9, 2008, Pages 1381-1390

  Sheikh, N A ^a   Jones, L A ^a  

^a Dendreon   (United States)

Author keywords

Activation; Antigen processing; APC; CD54; Upregulation

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BIOLOGICAL MARKER; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR1 ANTIGEN; HLA DRBETA1 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANALYTICAL PARAMETERS; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYBRIDOMA; HYBRIDOMA CELL CULTURE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SIPULEUCEL T; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ANTIGEN PRESENTATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTES; PHENOTYPE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TISSUE EXTRACTS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 45849146906     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0474-9     Document Type: Article

References (33)

1. Adams DO, Hamilton TA (1984) The cell biology of macrophage activation. Annu Rev Immunol 2:283-318
2. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175-2182
3. Burch PA, Groghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S (2004) Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-induced prostate cancer: a phase 2 trial. Prostate 60:197-204
4. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD (2004) LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity 20:58-599
5. Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203-209
6. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by IL-1 and Interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137: 245-254
7. Gaglia JL, Greenfield EA, Mattoo A, Sharpe AH, Freeman GJ, Kuchroo VK (2000) Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J Immunol 165:6091-6098
8. Gasson JC, Weisbrt RH, Kaufman SE (1984) Purified human granulocyte-macrophage colony-simulating factor: direct action on neutrophils. Science 226:1339-1342
9. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515-548
10. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58
11. Hume D (2005) The mononuclear phagocyte system. Curr Opin Immunol 18:49-33
12. Jenkinson SR, Wiliams NA, Morgan DJ (2005) The role of intracellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J Immunol 174:3401-3407
13. Jones LA (2005) Part II: dendritic cancer vaccine potency tests. Biologicals 33:124-125
14. Laus R, Demao YM, Ruegg CL, Shapero MH, Slagle PH, Small E, Burch P, Valone FH (2001) Dendritic cell immunotherapy of cancer: preclinical models and early clinical experience. Cancer Res Therapy Control 11:1-10
15. Lebedeva T, Dustin ML, Sykulev Y (2005) ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 17:251-258
16. Loken MR, Brosman JM, Bach BA, Ault KA (1990) Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 11:453-459
17. Parameswaran N, SureshR, Bal V, Rath S, George A (2005) Lack of ICAM-1 on APCs during T cell priming leads to poor generation of central memory cells. J Immunol 175:2201-2211
18. Park JW, Melisko ME, Esserrman LJ, Jones LA, Wollan JB, Sims R (2007) Treatment with autologous antigen-presenting cells activated with the human epidermal growth factor receptor (HER-2)-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol 25:3680-3687
19. Petricciani J, Egan W, Vicari G, Furesz J, Schild G (2006) Potency assays for therapeutic live whole cell cancer vaccines. Biologicals 35:107-113
20. Poudrier J, Owens T (1994) CD54/intercellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation. J Exp Med 179:1417-1427
21. Seventeer GA, Shimizu Y, Horgan KJ, Shaw S (1990) The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144:4579-4586
22. Shankar G, Bader R, Lodge PA (2004) The COSTIM bioassay: a novel potency test for dendritic cells. J Immunol Methods 285:293-299
23. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y,Zhang L, Yuan ZR, Sheng H, Tan W, Das G, Devadas S (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 16:126-133
24. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone VH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894-3903
25. Small EJ, Schelhammer PF, Higano CS, Redfern CH, Neumanaitis JJ, Valone FH, Verjee SS, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094
26. Somersalo K, Anikeeva N, Sims TN, Thomas VK, Strong RK, Spies T, Sykulev Y, Dustin ML (2004) Cytotoxic T lypmhocytes form an antigen-independent ring junction. J Clin Invest 113:49-57
27. Steinman RM, Witmer MD (1978) Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75:5132-5136
28. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16:3-9
29. Tohma S, Ramberg JE, Lipsky PE (1992) Expression and distribution of CD11a/CD18 and CD54 during human T cell-B cell interactions. J Leukoc Biol 52:97-103
30. Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L (2004) Role of cross-talk between IFNα-induced monocyte derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 172:5363-5370
31. Vidovic D, Graddis TJ, Stepan LP, Zaller DM, Laus R (2003) Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC. Human Immunol 64:238-244
32. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK (1989) Recombinant human granulocyte/macrophage colony stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor α and interferon in cancer patients. Blood 73:643-646
33. From a presentation at the Cellular, Tissue and Gene Therapies Advisory Committee meeting. January 2007 posting date. Gavin D. Perspectives on potency assays for complex biological products. Food and Drug Administration, Center for Biologics Research and Evaluation, Office of Cellular, Tissue and gene Therapy. http://www.fda.gov/cber/genetherapy/cmc012807dg.htm